LT2970191T - Piridino dariniai kaip transfekcijos metu pertvarkytos (ret) kinazės inhibitoriai - Google Patents

Piridino dariniai kaip transfekcijos metu pertvarkytos (ret) kinazės inhibitoriai

Info

Publication number
LT2970191T
LT2970191T LTEP14713598.2T LT14713598T LT2970191T LT 2970191 T LT2970191 T LT 2970191T LT 14713598 T LT14713598 T LT 14713598T LT 2970191 T LT2970191 T LT 2970191T
Authority
LT
Lithuania
Prior art keywords
ret
kinase inhibitors
pyridine derivatives
during transfection
rearranged during
Prior art date
Application number
LTEP14713598.2T
Other languages
English (en)
Lithuanian (lt)
Inventor
Hilary Schenck Eidam
Michael P. Demartino
Zhen Gong
Amy Huiping GUAN
Kaushik Raha
Chengde Wu
Haiying Yang
Haiyu Yu
Zhiliu Zhang
Mui Cheung
Original Assignee
Glaxosmithkline Intellectual Property Development Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Intellectual Property Development Limited filed Critical Glaxosmithkline Intellectual Property Development Limited
Publication of LT2970191T publication Critical patent/LT2970191T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
LTEP14713598.2T 2013-03-15 2014-03-14 Piridino dariniai kaip transfekcijos metu pertvarkytos (ret) kinazės inhibitoriai LT2970191T (lt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2013072683 2013-03-15
CN2013090059 2013-12-20
CN2014072449 2014-02-24
PCT/IB2014/059817 WO2014141187A1 (en) 2013-03-15 2014-03-14 Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors

Publications (1)

Publication Number Publication Date
LT2970191T true LT2970191T (lt) 2017-03-10

Family

ID=50390154

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP14713598.2T LT2970191T (lt) 2013-03-15 2014-03-14 Piridino dariniai kaip transfekcijos metu pertvarkytos (ret) kinazės inhibitoriai

Country Status (33)

Country Link
US (2) US9382238B2 (OSRAM)
EP (1) EP2970191B1 (OSRAM)
JP (1) JP2016516026A (OSRAM)
CN (1) CN105051027A (OSRAM)
AU (1) AU2014229233B2 (OSRAM)
BR (1) BR112015023618A2 (OSRAM)
CA (1) CA2905627A1 (OSRAM)
CL (1) CL2015002514A1 (OSRAM)
CR (1) CR20150490A (OSRAM)
CY (1) CY1118730T1 (OSRAM)
DK (1) DK2970191T3 (OSRAM)
DO (1) DOP2015000244A (OSRAM)
EA (1) EA029296B1 (OSRAM)
ES (1) ES2616655T3 (OSRAM)
HR (1) HRP20170363T1 (OSRAM)
HU (1) HUE033423T2 (OSRAM)
IL (1) IL241161A0 (OSRAM)
LT (1) LT2970191T (OSRAM)
ME (1) ME02664B (OSRAM)
MX (1) MX2015012286A (OSRAM)
NZ (1) NZ628388A (OSRAM)
PE (1) PE20151538A1 (OSRAM)
PH (1) PH12015502044A1 (OSRAM)
PL (1) PL2970191T3 (OSRAM)
PT (1) PT2970191T (OSRAM)
RS (1) RS55710B1 (OSRAM)
SG (1) SG11201506695UA (OSRAM)
SI (1) SI2970191T1 (OSRAM)
SM (1) SMT201700152T1 (OSRAM)
TW (1) TW201524958A (OSRAM)
UA (1) UA115264C2 (OSRAM)
UY (1) UY35465A (OSRAM)
WO (1) WO2014141187A1 (OSRAM)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2628418T3 (es) 2010-05-20 2017-08-02 Array Biopharma, Inc. Compuestos macrocíclicos como inhibidores de la TRK cinasa
US20170283404A1 (en) * 2014-09-08 2017-10-05 Glaxosmithkline Intellectual Property Development Limited Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
PT3191450T (pt) * 2014-09-10 2019-05-29 Glaxosmithkline Ip Dev Ltd Derivados de piridona como inibidores da quinase rearranjada durante a transfecção (ret)
EA032030B1 (ru) 2014-09-10 2019-03-29 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения в качестве ингибиторов реаранжированной во время трансфекции (ret) киназы
WO2016127074A1 (en) 2015-02-06 2016-08-11 Blueprint Medicines Corporation 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors
RS61485B1 (sr) 2015-07-16 2021-03-31 Array Biopharma Inc Supstituisana pirazolo [1,5-a] piridinska jedinjenja kao inhibitori ret kinaze
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
IL302209B2 (en) 2015-11-02 2024-06-01 Blueprint Medicines Corp Inhibitors of ret
WO2017145050A1 (en) 2016-02-23 2017-08-31 Glaxosmithkline Intellectual Property Development Limited Pyridylpyridone derivative useful as a ret kinase inhibitor in the treatment of ibs and cancer
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
WO2017161269A1 (en) 2016-03-17 2017-09-21 Blueprint Medicines Corporation Inhibitors of ret receptor tyrosine kinases
CN109996556A (zh) 2016-05-13 2019-07-09 分子医学研究院 治疗与ilc3细胞相关之疾病的方法
WO2018017983A1 (en) 2016-07-22 2018-01-25 Blueprint Medicines Corporation Compounds useful for treating disorders related to ret
JP2018052878A (ja) 2016-09-29 2018-04-05 第一三共株式会社 ピリジン化合物
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
EP3571203B1 (en) 2017-01-18 2023-06-07 Array BioPharma Inc. Substituted pyrazolo[1,5-a]pyrazine compounds as ret kinase inhibitors
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
CN110891573A (zh) 2017-05-15 2020-03-17 缆图药品公司 Ret抑制剂和mtorc1抑制剂的组合及其用于治疗由异常ret活性介导的癌症的用途
US10093648B1 (en) * 2017-09-22 2018-10-09 Celgene Corporation Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione hemihydrate, compositions and methods of use thereof
TWI876442B (zh) * 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
CA3087578C (en) 2018-01-18 2023-08-08 Array Biopharma Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
CN111615514B (zh) 2018-01-18 2022-10-11 奥瑞生物药品公司 作为ret激酶抑制剂的取代的吡唑并[4,3-c]吡啶化合物
PT3773589T (pt) 2018-04-03 2024-02-06 Blueprint Medicines Corp Inibidor de ret para utilização no tratamento de cancro com alteração de ret
CN109096264B (zh) * 2018-08-28 2019-08-23 山东理工职业学院 Ret抑制剂及其制备方法、组合物和用途
JP2022500383A (ja) 2018-09-10 2022-01-04 アレイ バイオファーマ インコーポレイテッド Retキナーゼ阻害剤としての縮合複素環式化合物
EP3956330A4 (en) 2019-04-18 2023-01-18 The Johns Hopkins University SUBSTITUTED 2-AMINO-PYRAZOLYL-[1,2,4]TRIAZOLO[1,5A]PYRIDINE DERIVATIVES AND THEIR USE
JP7461605B2 (ja) * 2020-02-20 2024-04-04 広州白雲山医薬集団股▲フン▼有限公司白雲山制薬総廠 キノリン系化合物
AR121914A1 (es) * 2020-04-27 2022-07-20 Lilly Co Eli Compuestos útiles para inhibir la quinasa ret
CA3183728A1 (en) 2020-05-29 2021-12-02 Blueprint Medicines Corporation Solid forms of pralsetinib
CN115803316B (zh) * 2020-07-23 2024-12-06 深圳晶泰科技有限公司 吡啶酮类化合物及其制备方法和应用
TWI790810B (zh) 2020-11-06 2023-01-21 美商美國禮來大藥廠 Ret激酶抑制劑
CA3222177A1 (en) 2021-06-03 2022-12-08 Fundacao D. Anna De Sommer Champalimaud E Dr. Carlos Montez Champalimaud Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit
CN115626880B (zh) * 2022-11-15 2023-11-14 常州大学 3-硝基-5-氰基三氟甲苯的合成方法
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法
EP4650002A1 (en) * 2024-05-15 2025-11-19 Ludwig-Maximilians-Universität Aniline-based modulators of the nuclear receptor tlx (nr2e1)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK1812002A3 (en) 1999-08-12 2003-02-04 Pharmacia Italia Spa 3(5)-Amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
AU2002215053A1 (en) * 2000-11-27 2002-06-24 Pharmacia Italia S.P.A. Phenylacetamido- pyrazole derivatives and their use as antitumor agents
DE10201764A1 (de) 2002-01-18 2003-07-31 Bayer Cropscience Ag Substituierte 4-Aminopyridin-Derivate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
JP2010506879A (ja) * 2006-10-16 2010-03-04 ノバルティス アーゲー プロテインキナーゼ阻害剤として有用なフェニルアセトアミド
WO2008058341A1 (en) * 2006-11-15 2008-05-22 Cytopia Research Pty Ltd Inhibitors of kinase activity
WO2011022473A1 (en) * 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
US9073895B2 (en) 2010-12-16 2015-07-07 Boehringer Ingelheim International Gmbh Biarylamide inhibitors of leukotriene production
US8937071B2 (en) 2013-03-15 2015-01-20 Glaxosmithkline Intellectual Property Development Limited Compounds as rearranged during transfection (RET) inhibitors

Also Published As

Publication number Publication date
RS55710B1 (sr) 2017-07-31
CL2015002514A1 (es) 2016-02-05
DOP2015000244A (es) 2015-12-31
US9382238B2 (en) 2016-07-05
PE20151538A1 (es) 2015-11-18
US20160271123A1 (en) 2016-09-22
PL2970191T3 (pl) 2017-07-31
IL241161A0 (en) 2015-11-30
EA029296B1 (ru) 2018-03-30
EP2970191B1 (en) 2016-12-21
SMT201700152T1 (it) 2017-05-08
HRP20170363T1 (hr) 2017-04-21
SG11201506695UA (en) 2015-09-29
DK2970191T3 (en) 2017-03-20
EA201591738A1 (ru) 2016-01-29
CN105051027A (zh) 2015-11-11
AU2014229233A1 (en) 2015-09-24
US20160002215A1 (en) 2016-01-07
BR112015023618A2 (pt) 2017-07-18
PT2970191T (pt) 2017-03-23
EP2970191A1 (en) 2016-01-20
JP2016516026A (ja) 2016-06-02
SI2970191T1 (sl) 2017-04-26
UA115264C2 (uk) 2017-10-10
US9789100B2 (en) 2017-10-17
AU2014229233B2 (en) 2016-08-11
PH12015502044A1 (en) 2016-01-18
ES2616655T3 (es) 2017-06-13
NZ628388A (en) 2016-09-30
MX2015012286A (es) 2016-05-31
HUE033423T2 (en) 2017-11-28
CA2905627A1 (en) 2014-09-18
UY35465A (es) 2014-10-31
CR20150490A (es) 2015-11-20
WO2014141187A1 (en) 2014-09-18
TW201524958A (zh) 2015-07-01
CY1118730T1 (el) 2017-07-12
ME02664B (me) 2017-06-20

Similar Documents

Publication Publication Date Title
IL241161A0 (en) History of pyridine as inhibitors of rearrangement during transfection (ret) kinases
IL250908A0 (en) Pyridone derivatives as ret kinase inhibitors
IL245660A0 (en) History of aminopyridines as tam family kinase inhibitors
ZA201406078B (en) Pyrazolo - triazine derivatives as selective cyclin- dependent kinase inhibitors
SG11201600062RA (en) Pyrimidine derivatives as kinase inhibitors
IL240327B (en) New pyrazole derivatives
IL244609B (en) History of 4-azaindole
ZA201507657B (en) Pyridin-4-yl derivatives
IL274874A (en) Dialkyl(oxido)-4 LAMDA-converted sulfenylidine nicotinamide derivatives as kinase inhibitors
ZA201508968B (en) Imidazo-triazine derivatives as pde10 inhibitors
IL244029A0 (en) Deoxycytodine kinase inhibitors
PT2970232T (pt) Derivados de piridina substituída úteis como inibidores de cinase c-fms
ZA201506309B (en) Pyridine derivatives as rearranged during transfection (ret) kinase inhibitors
TH1501005474A (th) อนุพันธ์ไพริดีนในรูปสารยับยั้งไคเนสถูกจัดเรียงใหม่ในระหว่างการทรานส์เฟคชั่น (ret)